X T L Biopharmaceuticals Ltd (OTCQB:XTLBY)
| 6.08 Data as of May 16 |  0.00 / 0.00%Today’s Change | 4.95 Today|||52-Week Range 8.65 | -18.06% Year-to-Date |
Latest XTLBY News | Press Releases
No recent news for X T L Biopharmaceuticals Ltd.
Today’s Trading
| Previous close | 6.08 |
| Today’s open | n.a. |
| Day’s range | -- - -- |
| Volume | 0 |
| Average volume (3 months) | 992 |
| Market cap | $69.7M |
| Dividend yield | -- |
Data as of 05/16/2013
Growth & Valuation
| Earnings growth (last year) | +45.45% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | -- |
| Price/Sales | -- |
| Price/Book | 18.01 |
Competitors
| No competitors data available. |
Financials
| Last reporting date | September 8, 2008 |
| EPS forecast (this quarter) | -$0.04 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$1.2M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Biotechnology |
Chief Executive Officer & Director David Grossman |
Chief Financial Officer & Deputy CEO Ronen Twito, CPA |
Corporate headquarters Rehovot, -- |
Forecasts
